User profiles for G.W. Canonica
Giorgio Walter CanonicaProfessore Ordinario Allergologia e Malattie Respiratorie Verified email at unige.it Cited by 91992 |
Allergic rhinitis and its impact on asthma (ARIA) 2008
…, T Zuberbier, CE Baena‐Cagnani, GW Canonica… - Allergy, 2008 - Wiley Online Library
Allergic rhinitis is a symptomatic disorder of the nose induced after allergen exposure by an
immunoglobulin E (IgE)-mediated inflammation of the membranes lining the nose (1). It was …
immunoglobulin E (IgE)-mediated inflammation of the membranes lining the nose (1). It was …
Unmet clinical needs in chronic spontaneous urticaria. A GA2LEN task force report1
…, PJ Bousquet, J Bousquet, GW Canonica… - Allergy, 2011 - Wiley Online Library
To cite this article: Maurer M, Weller K, Bindslev‐Jensen C, Giménez‐Arnau A, Bousquet PJ,
Bousquet J, Canonica GW, Church MK, Godse KV, Grattan CEH, Greaves MW, Hide M, …
Bousquet J, Canonica GW, Church MK, Godse KV, Grattan CEH, Greaves MW, Hide M, …
Recommendations for standardization of clinical trials with Allergen Specific Immunotherapy for respiratory allergy. A statement of a World Allergy Organization (WAO) …
GW Canonica, CE Baena‐Cagnani, J Bousquet… - Allergy, 2007 - Wiley Online Library
Specific Immunotherapy for respiratory allergy is used since about one century and there is
now solid documentation of its efficacy. Nevertheless, the methods and experimental designs …
now solid documentation of its efficacy. Nevertheless, the methods and experimental designs …
Benefits of omalizumab as add‐on therapy in patients with severe persistent asthma who are inadequately controlled despite best available therapy (GINA 2002 step …
…, J Bousquet, KM Beeh, S Ramos, GW Canonica… - Allergy, 2005 - Wiley Online Library
Background: Patients with severe persistent asthma who are inadequately controlled despite
Global Initiative for Asthma (GINA) 2002 step 4 therapy are a challenging population with …
Global Initiative for Asthma (GINA) 2002 step 4 therapy are a challenging population with …
Allergic Rhinitis and its Impact on Asthma (ARIA) guidelines: 2010 revision
…, CE Baena-Cagnani, S Bonini, GW Canonica… - Journal of Allergy and …, 2010 - Elsevier
BACKGROUND: Allergic rhinitis represents a global health problem affecting 10% to 20% of
the population. The Allergic Rhinitis and its Impact on Asthma (ARIA) guidelines have been …
the population. The Allergic Rhinitis and its Impact on Asthma (ARIA) guidelines have been …
The EAACI/GA2LEN/EDF/WAO Guideline for the definition, classification, diagnosis, and management of urticaria: the 2013 revision and update
…, C Bindslev‐Jensen, Z Brzoza, GW Canonica… - Allergy, 2014 - Wiley Online Library
This guideline is the result of a systematic literature review using the ‘ G rading of R
ecommendations A ssessment, D evelopment and E valuation’ ( GRADE ) methodology and a …
ecommendations A ssessment, D evelopment and E valuation’ ( GRADE ) methodology and a …
Allergic Rhinitis and its Impact on Asthma (ARIA) guidelines—2016 revision
…, R Brignardello-Petersen, GW Canonica… - Journal of Allergy and …, 2017 - Elsevier
… Walter Canonica MD h , Thomas Casale MD i , Niels H. Chavannes MD, PhD j , Jaime Correia
de Sousa MD, PhD k , Alvaro A. Cruz MD, PhD l , … Bonini, GW Canonica, TB Casale, et al. …
de Sousa MD, PhD k , Alvaro A. Cruz MD, PhD l , … Bonini, GW Canonica, TB Casale, et al. …
The EAACI/GAČLEN/EDF/WAO guideline for the definition, classification, diagnosis and management of urticaria
…, Z Brzoza, R Buense Bedrikow, GW Canonica… - Allergy, 2018 - Wiley Online Library
This evidence‐ and consensus‐based guideline was developed following the methods
recommended by Cochrane and the Grading of Recommendations Assessment, Development …
recommended by Cochrane and the Grading of Recommendations Assessment, Development …
[PDF][PDF] Consensus statement* on the treatment of allergic rhinitis
1. Introduction Allergic rhinitis (AR) is a high-prevalence disease in many developed
countries, affecting about 10±20% of the general population (1±5). Several studies based on …
countries, affecting about 10±20% of the general population (1±5). Several studies based on …
Efficacy and safety of dupilumab in patients with severe chronic rhinosinusitis with nasal polyps (LIBERTY NP SINUS-24 and LIBERTY NP SINUS-52): results from two …
…, JF Maspero, C Hopkins, H Olze, GW Canonica… - The Lancet, 2019 - thelancet.com
Background Patients with chronic rhinosinusitis with nasal polyps (CRSwNP) generally
have a high symptom burden and poor health-related quality of life, often requiring recurring …
have a high symptom burden and poor health-related quality of life, often requiring recurring …